RevGenetics has introduced DiBerberine 300x, an advanced dihydroberberine supplement engineered to enhance bioavailability through innovative enteric-coated technology. Each capsule contains a proprietary blend of 500 mg DiBerberine and RGBooster1, a novel flavonoid complex designed to address key challenges in berberine absorption, specifically stomach acid degradation and P-glycoprotein efflux.

This development is significant for the longevity and healthspan research community, as improved absorption of berberine could amplify its therapeutic potential, particularly in metabolic health and age-related conditions. A 2022 study highlighted that a 100 mg dose of dihydroberberine resulted in approximately 6.7 times greater plasma exposure compared to a standard 500 mg dose of berberine HCl, suggesting a promising avenue for enhancing the efficacy of berberine-based interventions.

For researchers and practitioners, the launch of DiBerberine 300x underscores the importance of bioavailability in supplement formulation, potentially paving the way for more effective longevity therapeutics.

Source: longevity.technology